Pre market mover
CHICAGO, Dec 12 (Reuters) - MedImmune Inc.(MEDI.O: Quote, Profile, Research) , maker of the FluMist nasal spray vaccine, said on Monday its next-generation nasal flu vaccine CAIV-T showed a statistically significant reduction in flu cases compared with the injectable flu vaccine.
MedImmune said the study of cold-adapted influenza vaccine, trivalent or CAIV-T showed 8.6 percent of patients taking conventional flu shows came down with the flu, compared with just 3.9 percent taking the nasal vaccine.
CAIV-T is a refrigerated version of FluMist, a frozen vaccine currently approved to prevent influenza in healthy children and adolescents, 5 to 17 years of age, and healthy adults, 18 to 49 years of age.
The company is seeking U.S. regulatory approval to sell its vaccine as an alternative to the injectable flu vaccine beginning in the 2007 flu season. |
